An engineered immune-signaling protein placed into the bladder alongside an older bacteria-based bladder treatment, for adults whose early-stage bladder cancer returned after that treatment and who want to avoid bladder removal. Most clear their cancer and keep their bladder, with mostly mild urinary side effects. Costly, multi-year, and unproven in other cancers. (Full Review)

Protocol

Induction

400 μg + BCG weekly × 6 weeks

Second 6-week course at month 3 if no complete response

Maintenance

Weekly × 3 at months 4, 7, 10, 13, 19

Up to 15 maintenance doses, ~37 months in responders

Route

Intravesical via catheter

Retained in bladder; given in clinic by trained personnel

Time to effect

Response check

~3 months

First cystoscopy; complete response also confirmed at 6 months

Benefits

High: Complete response in carcinoma in situ after BCG failure; durable response and bladder preservation

Medium: Disease control in papillary-only disease; bladder-specific survival

Low: Favorable tolerability enabling continued bladder-sparing therapy

Speculative: Activity in other tumor types

Contraindications

Active, untreated urinary tract infection

Gross hematuria

Immunocompromised states (systemic immunosuppression, active immunodeficiency)

Known hypersensitivity to the components

Patients in whom BCG is contraindicated

Febrile illness

Recent traumatic catheterization

Muscle-invasive disease (≥ stage T2)

Key Interactions

Immunosuppressant drugs (prednisone, methotrexate, tacrolimus, TNF inhibitors)

Antimicrobials active against BCG (ciprofloxacin, antituberculous agents)

Additive immune-modulating agents (pembrolizumab, nivolumab)

Recent transurethral resection

Risk & Side Effects

High: Local urinary adverse events; urinary tract infection

Medium: Increased serum creatinine; BCG-related systemic and infectious effects

Low: Immune-related adverse events

Speculative: Long-term and rare systemic risks

Monitoring

Marker	Target	Why
Cystoscopy + biopsy/cytology	No detectable cancer (complete response)	Primary measure of treatment success
Urine cytology	Negative for malignant cells	Detects residual or recurrent high-grade disease
Serum creatinine	Within individual baseline / normal renal range	Detects the reported creatinine increases
Urinalysis	No active infection; no significant new hematuria	Screens for UTI and bleeding before instillation
Complete blood count (CBC)	Within normal limits	Monitors for systemic or infectious effects

Cadence: Cystoscopy at ~3 and 6 months, then periodically; renal and urinary labs at baseline and periodically through the up-to-37-month course

Qualitative Assessment

Urinary symptom burden (dysuria, frequency, urgency)
Systemic symptoms (fever, fatigue, flu-like illness after instillation)
Functional well-being (energy, ability to keep up with the visit schedule)

ANKTIVA to Treat Cancer

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment